Posted by Michael Wonder on 21 May 2025
New weekly treatment option approved for patients with haemophilia B
21 May 2025 - Final draft guidance published today recommends marstacimab (Hympavzi; Pfizer) for treating severe haemophilia B in patients 12 years and over.
Marstacimab is the first subcutaneous injection for severe haemophilia B and today’s decision comes just weeks after the treatment received its UK licence.
